Evidence map›Paper›PMID 39467871›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

How do patients with head and neck cancer and low skeletal muscle mass experience cisplatin-based chemoradiotherapy? A qualitative study.

Anouk W M A Schaeffers, Maartje A van Beers, Lot A Devriese, F W José Klomp, Chantal F M Westerink-van den Brink, Ernst J Smid, Remco de Bree, Caroline M Speksnijder

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anouk W M A SchaeffersDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, G05.122, P.O. Box 85.500, 3508 GA, Utrecht, The Netherlands.
Maartje A van BeersDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, G05.122, P.O. Box 85.500, 3508 GA, Utrecht, The Netherlands.
Lot A DevrieseDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
F W José KlompDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, G05.122, P.O. Box 85.500, 3508 GA, Utrecht, The Netherlands.
Chantal F M Westerink-van den BrinkDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, G05.122, P.O. Box 85.500, 3508 GA, Utrecht, The Netherlands.
Ernst J SmidDepartment of Radiotherapy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Remco de BreeDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, G05.122, P.O. Box 85.500, 3508 GA, Utrecht, The Netherlands.
Caroline M SpeksnijderDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, G05.122, P.O. Box 85.500, 3508 GA, Utrecht, The Netherlands. C.M.Speksnijder@umcutrecht.nl.

Funding

ZonMw 10140021910002
6 · The paper itself

Abstract

backgroundPatients with head and neck squamous cell carcinoma (HNSCC) face several physical, emotional, and psychological challenges throughout treatment. Cisplatin-based chemoradiotherapy (CRT) is an effective but toxic treatment, with an increased risk for toxicities in patients with low skeletal muscle mass (SMM). Consequently, these patients are anticipated to experience greater treatment-related difficulties. We aimed to explore the experiences of patients with HNSCC and low SMM regarding cisplatin-based CRT.

methodsA descriptive qualitative study was conducted, interviewing seven patients 3 months after CRT using a topic guide. Thematic analysis of semi-structured interviews was conducted, to create a multi-dimensional understanding of patients' experiences during and after cisplatin-based CRT.

resultsPrior to CRT themes included pre-treatment information, expectations towards treatment and trial, psychosocial circumstances, and supporting network. During CRT themes included toxicities, psychosocial impact, and supporting network. After CRT themes included reflection on period during CRT, psychosocial circumstances, informal support from networks and healthcare workers, and ongoing toxicities.

conclusionMost patients experience cisplatin-based CRT as a life-changing and distressing life event but cope through various strategies and supporting networks. Tailored counseling, ideally with on-demand consultations, is recommended. No differences were noted in patients' perceptions of their cisplatin regimen.

Indexed as

Antineoplastic AgentsChemoradiotherapyCisplatinHead and Neck NeoplasmsQualitative ResearchSquamous Cell Carcinoma of Head and NeckAdaptation, PsychologicalAdultAgedFemaleHumansInterviews as TopicMaleMiddle AgedMuscle, SkeletalSocial SupportAntineoplastic AgentsCisplatinChemoradiationCisplatinDose limiting toxicityHead and neck cancerQualitative researchSkeletal muscle mass

Identifiers

PMID39467871
PMCPMC11519173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.